Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer

Background: Trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) are HER2-targeting antibody-drug conjugates (ADCs) with activity in HER2-mutant non-small cell lung cancer (NSCLC). Whether patients benefit from sequential HER2-directed ADCs therapy remains unknown. Methods: We conducted...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Daniel Reinhorn, MD, Jonathan Kuten, MD, MHA, Isabel Preeshagul, DO, MBS, Juliana Eng, MD, Kenneth Ng, MD, Alexander Drilon, MD, Jamie Chaft, MD, Fernando C. Santini, MD, Mark M. Awad, MD, PhD
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Elsevier 2026-07-01
سلاسل:	JTO Clinical and Research Reports
الموضوعات:	Non-small cell lung cancer ERBB2 mutation Antibody-drug conjugate Trastuzumab deruxtecan Trastuzumab emtansine Treatment sequencing
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S2666364326000755
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!